Pseudohypoaldosteronism type 2 (PHA2) is a rare autosomal dominant form of human arterial hypertension, associated with hyperkalemia and hyperchloremic metabolic acidosis. WNK1 and WNK4 are two of the genes mutated in PHA2 patients. This review focuses on the mechanisms by which deletions of the first intron of WNK1 found in PHA2 patients trigger the disease.
INTRODUCTION
Secretion of the mineralocorticoid hormone aldosterone is physiologically stimulated by changes in blood volume and pressure, via angiotensin II, and changes in plasma K þ , directly sensed by K þ channels expressed in the adrenal cortex. In the first case, aldosterone promotes Na þ reabsorption without altering K þ balance while it stimulates K þ secretion but does not affect Na þ homeostasis following an increase in plasma K þ . Pseudohypoaldosteronism type 2 (PHA2), also known as Gordon's syndrome or familial hyperkalemic hypertension, is a rare autosomal dominant disease which associates net positive Na þ balance with renal K þ retention as patients display hypertension, hyperkalemia and hyperchloremic metabolic acidosis [1] . These features are intriguing as hyperaldosteronism usually leads to increased Na þ reabsorption and K þ secretion, whereas hypoaldosteronism results in hypovolemia and hyperkalemia. Thus, identification of the pathophysiological mechanisms leading to the development of PHA2 should contribute to a better understanding of the so called 'aldosterone paradox' [2] .
Two of the genes responsible for PHA2, WNK1 and WNK4, were identified 10 years ago [3] . They encode two of the four members of the WNK [with no lysine (K)] family of serine-threonine kinases. The discovery of these mutations in a renal form of hypertension was unexpected as WNK1 had been identified only one year before through a search for new kinases of the MEK (MAPK or mitogen activated protein kinase kinase) family in the rat brain [4] or by the 'differential display' technique in colorectal cancer cell lines [5] .
This review focuses on WNK1. We will first describe the consequences of WNK1 PHA2 mutations on the expression of the kinase and then try to analyse how this deregulation of WNK1 expression could trigger the disease.
WNK1 PSEUDOHYPOALDOSTERONISM TYPE 2 MUTATIONS MODIFY ITS PATTERN OF EXPRESSION
While the mutations found in WNK4 are missense mutations, those found in WNK1 do not affect the coding sequence. They are large deletions of the first intron of WNK1 (22 and 41 kbp of a 60 kbp intron; Fig. 1a ). Quantitative RT-PCR showed that WNK1 mRNA level is increased in the leucocytes of PHA2 patients when compared with controls [3] .
The WNK1 gene gives rise to several isoforms through the use of alternative promoters and several alternatively spliced exons [6, 7] . The long isoform (L-WNK1), containing the whole kinase domain, is expressed ubiquitously, even in the nephron, wherein it is found at a low level in all segments. A shorter isoform, lacking kinase activity, is expressed in the distal convoluted tubule (DCT) and, to a lesser extent, in the connecting tubule (CNT), and is therefore called KS-WNK1, for kidneyspecific WNK1 (Fig. 1a ).
The clinical investigations could not allow the determination of which isoform is overexpressed and where. We therefore generated a mouse model bearing a transgene containing the mouse WNK1 gene deleted from the first intron and two reporter genes to monitor the changes in expression of L-WNK1 and KS-WNK1 [8] . Deletion of WNK1 first intron leads to a three-fold increase in L-WNK1 expression in the DCT and to KS-WNK1 ubiquitous expression, albeit at low levels.
The intronic deletion therefore induces a 'KS-WNK1-like' pattern of expression for L-WNK1, in addition to its normal expression, and vice versa. As depicted in Fig. 1a , KS-WNK1 transcription starts just upstream of exon 4a, specific to KS-WNK1 and located in intron 4. L-WNK1 (pP, proximal promoter) and KS-WNK1 promoters (rP, renal promoter) are therefore located upstream and downstream of intron 1, respectively. The deregulation of WNK1 isoforms expression could thus be explained by the deletion of one or several intronic insulators. An insulator is defined as a sequence that ensures position-independent transcription by insulating the expression of a gene from the effect of neighbouring sequences. In the case of WNK1, an insulator would prevent interaction between L-WNK1 ubiquitous regulatory elements and KS-WNK1 DCTspecific ones ( Fig. 1b ). We identified one insulator (C5, Fig. 1b ) whose deletion could lead to an interaction between regulatory modules controlling L-WNK1 and KS-WNK1 expression, resulting in L-WNK1 overexpression in the DCT-CNT and ubiquitous expression of KS-WNK1.
It is important to note that, in the DCT of control mice, KS-WNK1 transcript level is 80 times that of L-WNK1. Some studies have suggested that the L-WNK1-to-KS-WNK1 ratio could play a crucial role in the regulation of ion transport by WNKs in the DCT. However, in our mouse model, and probably in PHA2 individuals, KS-WNK1 expression remains much higher than that of L-WNK1 in the DCT. We are currently unable to explain or understand the massive expression of KS-WNK1 in the DCT. One possibility is that it interacts with molecules other than L-WNK1. As detailed below, KS-WNK1 acts as a dominant-negative of L-WNK1 [9] , and one study showed that it could also interfere with WNK3 [10] (Fig. 2 ). We therefore believe that the net increase in L-WNK1 expression in the DCT underlies PHA2. There is currently no animal model of WNK1-related PHA2 available, but in-vitro studies support this hypothesis.
ACTIVATION OF Na-Cl COTRANSPORTER AND HYPERTENSION IN PSEUDOHYPO-ALDOSTERONISM TYPE 2
One defining feature of PHA2 patients is their sensitivity to small doses of thiazide diuretics, which correct both the blood pressure (BP) and metabolic disorders. Thiazide diuretics block the activity of the Na-Cl cotransporter (NCC), specifically expressed in the DCT. In addition, PHA2 is the mirror image of Gitelman syndrome, which features salt wasting,
KEY POINTS
WNK1 is a serine-threonine kinase, which regulates Na þ , K þ and Cl À handling in the distal nephron.
Large deletions of the first intron of the WNK1 gene lead to overexpression of L-WNK1 in the distal convoluted tubule, thereby triggering the development of pseudohypoaldosteronism type 2 (PHA2).
Hypertension in PHA2 patients is caused by increased activity of the thiazide-sensitive Na-Cl cotransporter, following L-WNK1 activation.
The mechanisms leading to hyperkalemia and hyperchloremic metabolic acidosis in PHA2 patients still remain to be defined.
hypokalemia and metabolic alkalosis and is due to mutations in the gene encoding NCC [11] . Increased NCC expression and/or activity therefore seem to be a key feature of PHA2 pathogenesis. Accordingly, Mayan et al. [12] found an increased NCC quantity in urinary exosomes of PHA2 patients compared with unrelated controls. Studies performed in mouse models also support this hypothesis. Two models of WNK4-related PHA2 have been characterized [13, 14] . They exhibit all the clinical features of the disease and increased NCC activity (Table 1) [ 13-16,17 && ]. As in patients, genetic or pharmacological NCC inhibition results in the correction of all disorders. The following model has consequently been proposed: increased electroneutral Na þ /Cl À reabsorption by NCC would result not only in hypervolemia and thus hypertension but also in a decreased electrogenic Na þ reabsorption through the epithelial sodium (Na) channel (ENaC) and thus an impaired electrochemical gradient essential for K þ secretion by the renal outer medullary potassium (K) channel (ROMK), thereby leading to hyperkalemia. H þ secretion would be similarly impaired, thus explaining the metabolic acidosis.
Studies performed in Xenopus laevis oocytes and mammalian cell lines showed that L-WNK1 stimulates NCC membrane expression and activity (see below). The increased expression of L-WNK1 in the DCT of PHA2 patients would therefore lead to increased NCC activity, thereby triggering PHA2.
A first series of in-vitro studies showed that L-WNK1 does not directly regulate NCC activity but relieves the cotransporter from WNK4-mediated degradation through a lysosomal pathway [18, 19] . However, L-WNK1 could also regulate NCC via the phosphorylation of SPAK (STE20/SPS1-related proline/alanine-rich kinase [20, 21] ), which in turn interacts with and phosphorylates NCC, thus stimulating its activity. These two pathways are probably not independent as WNK4 is able to phosphorylate SPAK in vitro and SPAK phosphorylation is increased in WNK4-PHA2 mice. The physiological importance of SPAK in the regulation of NCC activity has recently been demonstrated in vivo [22 & ]. L-WNK1specific inactivation in mice, generated by genetrap [23 & ,24], does not allow the assessment of NCC regulation by L-WNK1 as it results in embryonic death [24, 25] , but data obtained in a mouse model of KS-WNK1 inactivation strongly suggest that L-WNK1 is indeed an activator of NCC in vivo ( Table 1) .
As described above, KS-WNK1 is devoid of kinase activity. It however binds to and inhibits L-WNK1 through the action of its inhibitory domain located downstream of the kinase domain ( Fig. 1a) . Accordingly, KS-WNK1 indirectly inhibits NCC by inhibiting L-WNK1 in vitro [9] . The inhibitory effect of KS-WNK1 has been demonstrated in vivo in mouse models of KS-WNK1 inactivation or overexpression [15, 16] . While KS-WNK1 À/À mice exhibit increased NCC phosphorylation and membrane expression, transgenic mice overexpressing KS-WNK1 in the whole distal nephron show decreased NCC phosphorylation and expression. The mechanisms by which NCC modulation is achieved in these models have not been clearly 
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Na + FIGURE 2. Regulation of ion transport by WNK1 in the distal nephron. In the distal convoluted tubule (DCT), the two WNK1 isoforms (L-WNK1 and KS-WNK1) interact with WNK3 and WNK4 to regulate the Na-Cl cotransporter (NCC). L-WNK1 and WNK3 activate whereas WNK4 and KS-WNK1 inhibit the cotransporter. L-WNK1 relieves NCC from WNK4-mediated inhibition; KS-WNK1 inhibits both L-WNK1 and WNK3. In addition, L-WNK1 phosphorylates SPAK, which in turn phosphorylates and activates NCC. WNK4 can also phopshorylate SPAK, suggesting that the two pathways are not independent. In the distal part of the DCT, the connecting tubule and the cortical collecting duct, L-WNK1 also regulates epithelial sodium channel (ENaC) and renal outer medullary potassium channel (ROMK) activity as well as paracellular Cl À transport, via the phosphorylation of claudins. L-WNK1 could activate ENaC by phosphorylating SGK1 while it inhibits ROMK membrane expression and therefore activity.
established. We quantified SPAK phosphorylation in KS-WNK1 À/À and were surprised to observe a slight decrease in phosphorylation rather than the expected increase on the Ser383 residue [15] . L-WNK1 can phosphorylate the Thr243 and Ser383 residues of mouse SPAK in vitro. While the requirement of the Thr residue for NCC phosphorylation is clearly demonstrated [22 & ], the function of the Ser residue is unknown. We therefore recently quantified the level of phosphorylation of the Thr243 residue and found that it is similar between KS-WNK1 þ/þ and KS-WNK1 À/À mice (Fig. 3) . Increased phosphorylation of NCC in KS-WNK1 À/À mice does not therefore seem to involve SPAK. The alternative mechanism by which this is achieved remains to be identified.
As described above, activation of NCC is believed to be an important factor for PHA2 pathogenesis. Surprisingly, KS-WNK1 À/À mice do not exhibit hyperkalemic hypertension nor hyperchloremic metabolic acidosis despite increased NCC activity (Table 1) , evidenced by the decreased aldosterone level [15] and salt-sensitive elevation of BP [16] . We proposed two hypotheses to explain this result: the level of NCC activation reached following KS-WNK1 inactivation is not sufficient, or NCC activation is necessary but not sufficient to induce PHA2. We tested the first hypothesis by comparing the level of expression and phosphorylation of NCC in KS-WNK1 À/À mice with that of the WNK4-PHA2 model generated by R. Lifton's group (TgWNK4 PHAII ). This experiment was complicated by the fact that the models were not on the same genetic background and that control mice from the two groups have a different level of NCC expression and phosphorylation at baseline. We therefore compared only the fold activation relative to their own controls. This study did not support a striking difference between the two models and thus favoured the second hypothesis about the implication of additional factors in WNK1-related PHA2.
HYPERKALEMIA IN PSEUDOHYPOALDOSTERONISM TYPE 2
The hyperkalemic effect of pharmacological or genetic inhibition of ENaC and, inversely, the hypokalemic effect of ENaC activation have been well described in humans and mice. Consequently, the hyperkalemia and metabolic acidosis in PHA2 patients are thought to result from the decreased Na þ reabsorption by ENaC, consecutive to the increased Na þ reabsorption by NCC in the DCT. Several sets of data, however, suggest that the situation is more complex. First, in KS-WNK1 À/À mice, ENaC expression and activity are decreased, as shown by their absence of response to amiloride, an ENaC blocker, but this inhibition does not result in hyperkalemia. Second, three studies have shown that ENaC is activated in both humans [26] and mice [14, 27] bearing PHA2-causing mutations. In particular, Yang et al. [14] showed that ENaC expression, measured by immunoblotting, and activity in microperfused cortical collecting ducts (CCD) of WNK4-PHA2 mice are increased and yet these mice display hyperkalemia. This activation could be a direct consequence of the PHA2 mutation, as shown in Xenopus oocytes [27] . It is possible however that the decreased flow rate and Na þ delivery to the CNT and CCD, consecutive to an increased Na þ reabsorption in the DCT, would lead to a reduced Na þ reabsorption even by an activated channel, thus inhibiting K þ secretion. This hypothesis, which remains to be tested by careful measurements of these parameters, is however not supported by the absence of hyperkalemia in individuals submitted to Na þ depletion and, again, in KS-WNK1 À/À mice.
Finally, coming back to L-WNK1, in-vitro studies have shown that L-WNK1 can activate ENaC via SGK1 phosphorylation [28] . The increased L-WNK1 in the DCT would then again stimulate rather than inhibit ENaC activity in this segment. In conclusion, ENaC inhibition does not seem to be a satisfying explanation for the hyperkalemia observed in PHA2 mice and patients.
In-vitro studies have shown that L-WNK1 and WNK4 could inhibit ROMK membrane expression by enhancing its clathrin-mediated endocytosis [29] [30] [31] [32] . Again, KS-WNK1 inhibits L-WNK1 and therefore stimulates ROMK activity, as demonstrated in vivo in mice overexpressing KS-WNK1 in the whole distal nephron [33] . The increased expression of L-WNK1 in the DCT of PHA2 patients could thus strongly inhibit K þ secretion by ROMK in this
Phosphorylation of the Thr243 residue of SPAK is not modified in KS-WNK1 À/À mice. Immunoblot of plasma membranes-enriched fractions isolated from the renal cortex of control and KS-WNK1 À/À males (n ¼ 5 per group) incubated with antiphospho-SPAK Thr243 antibody. Densitometric analysis shows that phosphorylation of SPAK on this residue is not modified in KS-WNK1 À/À mice compared with controls. Data are mean AE SEM. As reported in [22 & ], the phosphorylation level of this residue is very low in the kidney, thus explaining the weak signal obtained on this immunoblot. segment. Hyperkalemia is, however, corrected by the administration of thiazide diuretics in PHA2 patients, strongly suggesting that primary inhibition of ROMK by WNKs is not responsible for this disorder. A third possible explanation is the existence of a chloride shunt which would inhibit K þ secretion by altering the lumen negative transepithelial voltage. A strong kaliuretic response is indeed induced by perfusion of Na þ bicarbonate or sulfate but not by NaCl in PHA2 patients and WNK4-PHA2 mice [14, 34, 35] . L-WNK1 stimulates paracellular chloride permeability in vitro by increasing the phoshorylation of claudin-4, a pore-forming tight-junction protein that exhibits channel-like properties such as charge and size selectivity [36] . The mechanisms by which this is achieved remain to be defined.
It is of interest to briefly describe here yet another intriguing mouse model, which recently highlighted again the complex coordinated regulation of Na þ , K þ , Cl À and acid-base handling by the distal nephron [17 && ]. This model was generated by inactivation of the Kir5.1 K þ channel, present at the basolateral membrane of cells in the thick ascending limb of Henle's loop, DCT, CNT and CCD. Like PHA2 mice, it displays hyperchloremic metabolic acidosis and normal BP but this time associated with hypokalemia ( Table 1 ). NCC activity is increased, whereas that of ENaC is unchanged, but chronic administration of thiazide diuretics corrects only the metabolic acidosis, not the K þ loss.
ADDITIONAL WNK FUNCTION OUTSIDE THE KIDNEY
L-WNK1 is expressed in the cardiovascular system [37] . Interestingly, heterozygous L-WNK1 þ/À mice display a decreased BP with no alteration in their kidney function, suggesting that L-WNK1 could regulate BP in mice independently of its renal action and that vascular L-WNK1 could contribute to BP regulation. We showed that L-WNK1 haploinsufficiency strongly alters BP and vasoconstriction responses following a1-adrenergic receptors activation and almost abolishes the pressure-induced contractile (myogenic) response, an obligatory physiological adaptation to systemic BP variation for maintaining blood flow perfusion of organs [23 & ]. These alterations are associated with decreased phosphorylation of SPAK and Na-K-2Cl cotransporter 1 (NKCC1). Interestingly, a similar phenotype is observed in SPAK knock-out mice [38] . The contribution of vascular L-WNK1 and SPAK to the development of PHA2 remains to be demonstrated.
WNK4 is also expressed in the vasculature, wherein it reduces vasoconstriction in response to a1-adrenergic receptors stimulation through the inhibition of transient receptor potential canonical channel 3 (TRPC3) activity [39 & ]. As WNK4-PHA2 mutants fail to inhibit TRPC3 in vitro, impaired inhibition of vascular TRPC3 could contribute to the high BP observed in WNK4-related PHA2 patients, but this needs to be formally demonstrated in PHA2 mice and patients.
CONCLUSION
In conclusion, the net increase in the expression of the kinase isoform of WNK1 triggers the development of PHA2 in patients carrying a deletion of a large portion of WNK1 first intron. If the hypertension can be easily explained by increased Na þ reabsorption via the Na þ -Cl À cotransporter NCC, whose activity is stimulated by L-WNK1, the mechanisms underlying the hyperkalemia and hyperchloremic metabolic acidosis remain obscure. Once a WNK1-PHA2 mouse model becomes available, further in-depth studies of integrated Na þ , K þ , Cl À and acid-base handling by the distal nephron using what are often thought of as 'out-of-date' techniques such as microperfusion, micropuncture and electrophysiology will be needed in combination with novel technologies, such as phosphoproteomics, to unravel the mechanisms by which WNK1 PHA2 mutations trigger the development of these disorders.
